[{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"MycoMedica Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"MycoMedica Life Sciences \/ Obvious Ventures","highestDevelopmentStatusID":"1","companyTruncated":"MycoMedica Life Sciences \/ Obvious Ventures"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocin Prodrug","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MycoMedica Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"MycoMedica Life Sciences \/ MycoMedica Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"MycoMedica Life Sciences \/ MycoMedica Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by MycoMedica Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders such as depression.

                          Brand Name : EB-002

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 12, 2024

                          Lead Product(s) : Psilocin Prodrug

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Enveric Biosciences

                          Deal Size : $62.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The proceeds from the financing will be used to advance the company’s next stage of operations having psilocybine on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 01, 2022

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Obvious Ventures

                          Deal Size : $60.0 million

                          Deal Type : Financing

                          blank